JP2019529575A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529575A5 JP2019529575A5 JP2019538721A JP2019538721A JP2019529575A5 JP 2019529575 A5 JP2019529575 A5 JP 2019529575A5 JP 2019538721 A JP2019538721 A JP 2019538721A JP 2019538721 A JP2019538721 A JP 2019538721A JP 2019529575 A5 JP2019529575 A5 JP 2019529575A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- use according
- treatment
- compounds
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 12
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 12
- 229960005309 estradiol Drugs 0.000 claims description 12
- 229930182833 estradiol Natural products 0.000 claims description 12
- 201000010260 leiomyoma Diseases 0.000 claims description 12
- 201000009273 Endometriosis Diseases 0.000 claims description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 7
- 239000000583 progesterone congener Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims description 4
- 201000009274 endometriosis of uterus Diseases 0.000 claims description 4
- 208000007106 menorrhagia Diseases 0.000 claims description 4
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims 30
- 208000005641 Adenomyosis Diseases 0.000 claims 3
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims 3
- 208000000450 Pelvic Pain Diseases 0.000 claims 3
- 229960001652 norethindrone acetate Drugs 0.000 claims 3
- 235000012054 meals Nutrition 0.000 claims 2
- 230000027939 micturition Effects 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000037093 Menstruation Disturbances Diseases 0.000 claims 1
- 206010027339 Menstruation irregular Diseases 0.000 claims 1
- 206010046555 Urinary retention Diseases 0.000 claims 1
- 208000016599 Uterine disease Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000013872 defecation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000017708 myomatous neoplasm Diseases 0.000 claims 1
- 210000000754 myometrium Anatomy 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 201000004059 subependymal giant cell astrocytoma Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- -1 (1- (2,6-difluorobenzyl) -5-((dimethylamino) methyl) -3- (6-methoxy-3-pyridazinyl) -2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] Pyrimidine-6-yl) phenyl Chemical group 0.000 description 4
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 4
- 201000007954 uterine fibroid Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402150P | 2016-09-30 | 2016-09-30 | |
| US201662402034P | 2016-09-30 | 2016-09-30 | |
| US201662402055P | 2016-09-30 | 2016-09-30 | |
| US62/402,055 | 2016-09-30 | ||
| US62/402,034 | 2016-09-30 | ||
| US62/402,150 | 2016-09-30 | ||
| US201762492839P | 2017-05-01 | 2017-05-01 | |
| US62/492,839 | 2017-05-01 | ||
| US201762528409P | 2017-07-03 | 2017-07-03 | |
| US62/528,409 | 2017-07-03 | ||
| PCT/EP2017/074907 WO2018060501A2 (en) | 2016-09-30 | 2017-09-29 | Methods of treating uterine fibroids and endometriosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529575A JP2019529575A (ja) | 2019-10-17 |
| JP2019529575A5 true JP2019529575A5 (enExample) | 2020-11-12 |
| JP7043503B2 JP7043503B2 (ja) | 2022-03-29 |
Family
ID=60915460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538721A Active JP7043503B2 (ja) | 2016-09-30 | 2017-09-29 | 子宮筋腫及び子宮内膜症を治療する方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US11033551B2 (enExample) |
| EP (2) | EP4094766B1 (enExample) |
| JP (1) | JP7043503B2 (enExample) |
| CN (1) | CN110312512B (enExample) |
| AU (2) | AU2017336363B2 (enExample) |
| BR (1) | BR112019006227A2 (enExample) |
| CA (1) | CA3038879A1 (enExample) |
| CY (1) | CY1125254T1 (enExample) |
| DK (1) | DK3518933T4 (enExample) |
| ES (2) | ES2912929T5 (enExample) |
| FI (1) | FI3518933T4 (enExample) |
| HR (1) | HRP20220708T4 (enExample) |
| HU (2) | HUE059101T2 (enExample) |
| IL (2) | IL300580B2 (enExample) |
| LT (1) | LT3518933T (enExample) |
| MD (1) | MD3518933T4 (enExample) |
| MX (1) | MX2019003726A (enExample) |
| NZ (1) | NZ752916A (enExample) |
| PL (2) | PL3518933T5 (enExample) |
| PT (1) | PT3518933T (enExample) |
| RS (1) | RS63300B2 (enExample) |
| SI (1) | SI3518933T2 (enExample) |
| SM (1) | SMT202200254T1 (enExample) |
| WO (1) | WO2018060501A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| EP3518932B1 (en) | 2016-09-30 | 2024-11-13 | Sumitomo Pharma Switzerland GmbH | Treatment of prostate cancer |
| EP4509173A3 (en) | 2017-06-05 | 2025-06-04 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| US11980621B2 (en) | 2017-06-05 | 2024-05-14 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| JP2021531236A (ja) * | 2018-04-19 | 2021-11-18 | アッヴィ・インコーポレイテッド | 重度の月経出血を治療する方法 |
| MA54058A (fr) * | 2018-10-29 | 2021-09-08 | ObsEva SA | Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale |
| RU2711658C1 (ru) * | 2019-04-16 | 2020-01-20 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения наружного генитального эндометриоза |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| EP4009977A2 (en) * | 2019-08-08 | 2022-06-15 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| CN115279769A (zh) | 2019-10-10 | 2022-11-01 | 梦欧文科学有限责任公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 |
| EP4041738A1 (en) * | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| EP4107525A4 (en) * | 2020-02-19 | 2024-08-14 | Aspira Women's Health Inc. | Compositions for endometriosis assessment having improved specificity |
| CN113384581B (zh) * | 2020-03-12 | 2023-11-14 | 成都倍特药业股份有限公司 | 一种包含促性腺激素释放激素拮抗剂的药物组合物 |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
| EP4243829A1 (en) | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Methods of administering relugolix |
| EP4419530A1 (en) | 2021-10-18 | 2024-08-28 | Sumitomo Pharma Switzerland GmbH | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CN117069735A (zh) * | 2022-05-10 | 2023-11-17 | 北京海美源医药科技有限公司 | 一种高效合成瑞卢戈利的方法和其应用 |
| WO2024015934A2 (en) * | 2022-07-13 | 2024-01-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of diagnostic screening and early detection of adenomyosis |
| WO2024102620A2 (en) * | 2022-11-09 | 2024-05-16 | Tempest Therapeutics, Inc. | Triazolone compounds and uses thereof |
| WO2025106820A1 (en) * | 2023-11-16 | 2025-05-22 | University Of South Florida | Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub) |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US402055A (en) | 1889-04-23 | Water-motor | ||
| US402034A (en) | 1889-04-23 | Dumping-wagon | ||
| US492839A (en) | 1893-03-07 | Key for brake-shoes | ||
| US402150A (en) | 1889-04-30 | Broadcast seed-sower | ||
| US528409A (en) | 1894-10-30 | Denis ahern | ||
| FR2512732A1 (fr) | 1981-09-14 | 1983-03-18 | Raffinage Cie Francaise | Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications |
| US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| ECSP961635A (es) | 1996-01-11 | 1997-06-27 | Desprendimiento controlado de esteroides del recubrimiento de azucar | |
| ECSP971998A (es) | 1997-01-15 | 1998-04-07 | Desprendimiento controlado de esteroides del recubrimiento de azucar | |
| DE19815060A1 (de) | 1998-04-03 | 1999-10-14 | Jenapharm Gmbh | Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie |
| US6265393B1 (en) * | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| RU2233284C2 (ru) | 1999-03-24 | 2004-07-27 | Такеда Кемикал Индастриз, Лтд. | Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона |
| WO2001064683A1 (en) | 2000-02-29 | 2001-09-07 | Takeda Chemical Industries, Ltd. | Processes for the production of thienopyrimidine derivatives |
| WO2003064429A1 (en) | 2002-01-30 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Thienopyrimidines, process for preparing the same and use thereof |
| PT1591446E (pt) | 2003-01-29 | 2013-06-12 | Takeda Pharmaceutical | Compostos de tienopirimidina e sua utilização |
| CA2531508C (en) | 2003-07-07 | 2013-10-08 | Neurocrine Biosciences, Inc. | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| KR20080041662A (ko) | 2005-07-22 | 2008-05-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 조기 배란 예방제 |
| TWI386417B (zh) | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
| NZ580457A (en) | 2007-04-06 | 2012-03-30 | Neurocrine Biosciences Inc | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| WO2010026993A1 (ja) | 2008-09-03 | 2010-03-11 | 武田薬品工業株式会社 | 製剤における吸収性改善方法および吸収性が改善された製剤 |
| US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| KR20160088947A (ko) | 2010-06-16 | 2016-07-26 | 앙도르쉐르슈 인코포레이티드 | 에스트로겐-관련 질병의 치료 또는 예방 방법 |
| JP2012077020A (ja) | 2010-09-30 | 2012-04-19 | Mochida Pharmaceut Co Ltd | ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬 |
| PT3415517T (pt) | 2012-09-28 | 2022-05-13 | Takeda Pharmaceuticals Co | Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia |
| WO2014143669A1 (en) | 2013-03-15 | 2014-09-18 | AbbVie Inc . | Compositions for use in treating heavy menstrual bleeding and uterine fibroids |
| FI3263110T3 (fi) | 2015-02-26 | 2023-07-25 | Takeda Pharmaceuticals Co | Tabletti, joka käsittää metoksiureajohdannaista ja mannitolipartikkeleita |
| US9949974B2 (en) | 2015-09-01 | 2018-04-24 | Abbvie Inc. | Methods of adminstering elagolix |
| EP3518932B1 (en) | 2016-09-30 | 2024-11-13 | Sumitomo Pharma Switzerland GmbH | Treatment of prostate cancer |
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| US11980621B2 (en) | 2017-06-05 | 2024-05-14 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| EP4041738A1 (en) | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CN115279769A (zh) | 2019-10-10 | 2022-11-01 | 梦欧文科学有限责任公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
| EP4243829A1 (en) | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Methods of administering relugolix |
| EP4419530A1 (en) | 2021-10-18 | 2024-08-28 | Sumitomo Pharma Switzerland GmbH | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
-
2017
- 2017-09-29 ES ES17823018T patent/ES2912929T5/es active Active
- 2017-09-29 MD MDE20190880T patent/MD3518933T4/ro unknown
- 2017-09-29 HU HUE17823018A patent/HUE059101T2/hu unknown
- 2017-09-29 MX MX2019003726A patent/MX2019003726A/es unknown
- 2017-09-29 SM SM20220254T patent/SMT202200254T1/it unknown
- 2017-09-29 RS RS20220565A patent/RS63300B2/sr unknown
- 2017-09-29 BR BR112019006227-0A patent/BR112019006227A2/pt not_active Application Discontinuation
- 2017-09-29 FI FIEP17823018.1T patent/FI3518933T4/fi active
- 2017-09-29 JP JP2019538721A patent/JP7043503B2/ja active Active
- 2017-09-29 PL PL17823018.1T patent/PL3518933T5/pl unknown
- 2017-09-29 IL IL300580A patent/IL300580B2/en unknown
- 2017-09-29 AU AU2017336363A patent/AU2017336363B2/en active Active
- 2017-09-29 LT LTEPPCT/EP2017/074907T patent/LT3518933T/lt unknown
- 2017-09-29 CA CA3038879A patent/CA3038879A1/en active Pending
- 2017-09-29 HR HRP20220708TT patent/HRP20220708T4/hr unknown
- 2017-09-29 NZ NZ752916A patent/NZ752916A/en unknown
- 2017-09-29 DK DK17823018.1T patent/DK3518933T4/da active
- 2017-09-29 ES ES22162349T patent/ES3018413T3/es active Active
- 2017-09-29 EP EP22162349.9A patent/EP4094766B1/en active Active
- 2017-09-29 PT PT178230181T patent/PT3518933T/pt unknown
- 2017-09-29 SI SI201731123T patent/SI3518933T2/sl unknown
- 2017-09-29 HU HUE22162349A patent/HUE072130T2/hu unknown
- 2017-09-29 WO PCT/EP2017/074907 patent/WO2018060501A2/en not_active Ceased
- 2017-09-29 CN CN201780072987.XA patent/CN110312512B/zh active Active
- 2017-09-29 EP EP17823018.1A patent/EP3518933B2/en active Active
- 2017-09-29 PL PL22162349.9T patent/PL4094766T3/pl unknown
-
2019
- 2019-03-28 IL IL265700A patent/IL265700B2/en unknown
- 2019-03-29 US US16/370,299 patent/US11033551B2/en active Active
-
2021
- 2021-05-11 US US17/317,769 patent/US11793812B2/en active Active
-
2022
- 2022-06-02 CY CY20221100390T patent/CY1125254T1/el unknown
- 2022-07-15 US US17/866,201 patent/US11957684B2/en active Active
- 2022-09-30 AU AU2022241582A patent/AU2022241582C1/en active Active
-
2024
- 2024-01-30 US US18/427,579 patent/US20240165118A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI576107B (zh) | 釋放芳香化酶抑制劑及促孕素以治療子宮內膜異位症之非口服劑型 | |
| JP6124411B2 (ja) | プロゲステロンを含むモノリシック膣内リングならびにそれらの製造方法および使用 | |
| FI3518933T4 (fi) | Menetelmiä kohtumyooman ja endometrioosin hoitamiseksi | |
| JP2001520195A (ja) | 医薬の増強 | |
| RS60152B1 (sr) | Tapentadol za sprečavanje i lečenje depresije i anksioznosti | |
| FI3634419T3 (fi) | Gonadotropiinia vapauttavan hormonin antagonistin käsittävä annostusohjelma kohdun myoomien hoitamiseksi ja kuukautisten aiheuttaman verenhukan vähentämiseksi | |
| JP2005516904A (ja) | 緊急避妊のための薬学的組成物およびその用量処方 | |
| JP2009280621A (ja) | ヒトの性応答を調節するための組み合わせ治療 | |
| TW200404531A (en) | Synergistic combinations | |
| JP2023153796A (ja) | 子宮内膜症、子宮筋腫、多嚢胞性卵巣症候群又は腺筋症を治療するための医薬製剤 | |
| PL211402B1 (pl) | Zastosowanie dapoksetyny do leczenia lub zwalczania przedwczesnej ejakulacji | |
| JP2007517049A (ja) | 再発性病状を治療するための組成物および方法 | |
| TW201919632A (zh) | 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群或子宮腺肌症之醫藥調配物 | |
| KR20010029519A (ko) | 요실금 치료 방법 | |
| JP2021531236A (ja) | 重度の月経出血を治療する方法 | |
| WO2015127558A1 (en) | Methods and uses for inducing or facilitating micturition in a patient in need thereof | |
| AU2026200242A1 (en) | Method for treating endometriosis and providing effective contraception | |
| JP6840057B2 (ja) | 疼痛の慢性化を予防するためのタペンタドール | |
| CN1192145A (zh) | 最大限度地减少骨损失的方法 | |
| US11951095B2 (en) | Non-hormonal compositions and methods for male contraception | |
| AU780736B2 (en) | Treating endometriosis or infertility, or improving fertility | |
| EP2150257A2 (en) | Drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen | |
| JPWO1999020647A1 (ja) | ジエノゲストを有効成分とする子宮筋腫治療剤 | |
| US10485808B2 (en) | Selective progesterone receptor modulators (SPRM) and stabilized estrogen level in patient | |
| EP1827404A2 (en) | Use of alpha-adrenergic blockers for the treatment of dysmenorrhea |